Cepheid Shares Up 8.4 Percent on Anthrax Detection News

Feb 16, 2006

NEW YORK, Feb. 16 (GenomeWeb News) - Shares of Cepheid were up $.80, or 8.41 percent, at $10.31 in afternoon trading after the company this morning said that its GeneXpert real-time PCR platform for mobile anthrax detection had been licensed by biothreat agencies in Oakland, Mich., and Honolulu, Hawaii.

Breaking News

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.

Cepheid Shares Up 8.4 Percent on Anthrax Detection News

Bluestar Genomics Raises $70M in Series C Funding Round

Nuclera Acquires E Ink Digital Microfluidics Business

Sequencing Upstart Singular Genomics Files for $100M IPO

Researchers Reconstruct Ancient Human Gut Microbiomes From Paleofeces

ERS Genomics Licenses CRISPR Patents to GenScript Biotech

CellCarta Acquires Reveal Biosciences

Response Too Slow, Cautious

Pushed a Bit Later

AMA Announces Anti-Racism Effort

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

Ginkgo Bioworks Going Public Through Merger With SPAC

Severe COVID-19 Patients Show Antiviral Immunity Defects in Single-Cell Analysis

Invitae Sues Natera Alleging Infringement of Patent on DNA Sequencing Assembly Technique

Ancient Oral Microbiomes Reveal Similarities Between Neanderthals, Modern Humans

Also of Concern to WHO